These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28490192)

  • 1. LTX-315: a first-in-class oncolytic peptide that reprograms the tumor microenvironment.
    Sveinbjørnsson B; Camilio KA; Haug BE; Rekdal Ø
    Future Med Chem; 2017 Aug; 9(12):1339-1344. PubMed ID: 28490192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The oncolytic peptide LTX-315 induces cell death and DAMP release by mitochondria distortion in human melanoma cells.
    Eike LM; Yang N; Rekdal Ø; Sveinbjørnsson B
    Oncotarget; 2015 Oct; 6(33):34910-23. PubMed ID: 26472184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model.
    Camilio KA; Wang MY; Mauseth B; Waagene S; Kvalheim G; Rekdal Ø; Sveinbjørnsson B; Mælandsmo GM
    Breast Cancer Res; 2019 Jan; 21(1):9. PubMed ID: 30670061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade.
    Yamazaki T; Pitt JM; Vétizou M; Marabelle A; Flores C; Rekdal Ø; Kroemer G; Zitvogel L
    Cell Death Differ; 2016 Jun; 23(6):1004-15. PubMed ID: 27082453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors.
    Spicer J; Marabelle A; Baurain JF; Jebsen NL; Jøssang DE; Awada A; Kristeleit R; Loirat D; Lazaridis G; Jungels C; Brunsvig P; Nicolaisen B; Saunders A; Patel H; Galon J; Hermitte F; Camilio KA; Mauseth B; Sundvold V; Sveinbjørnsson B; Rekdal Ø
    Clin Cancer Res; 2021 May; 27(10):2755-2763. PubMed ID: 33542073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The oncolytic peptide LTX-315 triggers necrotic cell death.
    Forveille S; Zhou H; Sauvat A; Bezu L; Müller K; Liu P; Zitvogel L; Pierron G; Rekdal Ø; Kepp O; Kroemer G
    Cell Cycle; 2015; 14(21):3506-12. PubMed ID: 26566869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and structural optimization of oncolytic peptide LTX-315.
    Song M; Liu Q; Yao JF; Wang YT; Ma YN; Xu H; Yu QY; Li Z; Du SS; Qi YK
    Bioorg Med Chem; 2024 Jun; 107():117760. PubMed ID: 38762978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The oncolytic peptide LTX-315 triggers immunogenic cell death.
    Zhou H; Forveille S; Sauvat A; Yamazaki T; Senovilla L; Ma Y; Liu P; Yang H; Bezu L; Müller K; Zitvogel L; Rekdal Ø; Kepp O; Kroemer G
    Cell Death Dis; 2016 Mar; 7(3):e2134. PubMed ID: 26962684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization.
    Zhou H; Forveille S; Sauvat A; Sica V; Izzo V; Durand S; Müller K; Liu P; Zitvogel L; Rekdal Ø; Kepp O; Kroemer G
    Oncotarget; 2015 Sep; 6(29):26599-614. PubMed ID: 26378049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The oncolytic compound LTX-401 targets the Golgi apparatus.
    Zhou H; Sauvat A; Gomes-da-Silva LC; Durand S; Forveille S; Iribarren K; Yamazaki T; Souquere S; Bezu L; Müller K; Leduc M; Liu P; Zhao L; Marabelle A; Zitvogel L; Rekdal Ø; Kepp O; Kroemer G
    Cell Death Differ; 2016 Dec; 23(12):2031-2041. PubMed ID: 27588704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide.
    Haug BE; Camilio KA; Eliassen LT; Stensen W; Svendsen JS; Berg K; Mortensen B; Serin G; Mirjolet JF; Bichat F; Rekdal Ø
    J Med Chem; 2016 Apr; 59(7):2918-27. PubMed ID: 26982623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ANTICANCER IMMUNOGENIC POTENTIAL OF ONCOLYTIC PEPTIDES: RECENT ADVANCES AND NEW PROSPECTS.
    Khranovska N; Skachkova O; Gorbach O; Semchuk I; Shvets Y; Komarov I
    Exp Oncol; 2024 May; 46(1):3-12. PubMed ID: 38852058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells.
    Yamazaki T; Wennerberg E; Hensler M; Buqué A; Kraynak J; Fucikova J; Zhou XK; Sveinbjørnsson B; Rekdal Ø; Demaria S; Galluzzi L
    Oncoimmunology; 2021; 10(1):1962592. PubMed ID: 34408925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model.
    Nestvold J; Wang MY; Camilio KA; Zinöcker S; Tjelle TE; Lindberg A; Haug BE; Kvalheim G; Sveinbjørnsson B; Rekdal Ø
    Oncoimmunology; 2017; 6(8):e1338236. PubMed ID: 28920000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced T-lymphocyte infiltration in a desmoid tumor of the thoracic wall in a young woman treated with intratumoral injections of the oncolytic peptide LTX-315: a case report.
    Jebsen NL; Apelseth TO; Haugland HK; Rekdal Ø; Patel H; Gjertsen BT; Jøssang DE
    J Med Case Rep; 2019 Jun; 13(1):177. PubMed ID: 31177991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three Rounds of Stability-Guided Optimization and Systematical Evaluation of Oncolytic Peptide LTX-315.
    Fu XY; Yin H; Chen XT; Yao JF; Ma YN; Song M; Xu H; Yu QY; Du SS; Qi YK; Wang KW
    J Med Chem; 2024 Mar; 67(5):3885-3908. PubMed ID: 38278140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Novel Oncolytic Compound LTX-401 Induces Antitumor Immune Responses in Experimental Hepatocellular Carcinoma.
    Mauseth B; Camilio KA; Shi J; Hammarström CL; Rekdal Ø; Sveinbjørnsson B; Line PD
    Mol Ther Oncolytics; 2019 Sep; 14():139-148. PubMed ID: 31211244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor lysis with LTX-401 creates anticancer immunity.
    Xie W; Mondragón L; Mauseth B; Wang Y; Pol J; Lévesque S; Zhou H; Yamazaki T; Eksteen JJ; Zitvogel L; Sveinbjørnsson B; Rekdal Ø; Kepp O; Kroemer G
    Oncoimmunology; 2019; 8(7):1594555. PubMed ID: 31143516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic administration of polymersomal oncolytic peptide LTX-315 combining with CpG adjuvant and anti-PD-1 antibody boosts immunotherapy of melanoma.
    Xia Y; Wei J; Zhao S; Guo B; Meng F; Klumperman B; Zhong Z
    J Control Release; 2021 Aug; 336():262-273. PubMed ID: 34174350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CCR5 Therapy Circumvents Immune Cell Exploitation by Tumors.
    Cancer Discov; 2016 Jun; 6(6):571. PubMed ID: 27125549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.